New hope drug enters human testing for tough cancers

NCT ID NCT05490472

Recruiting now Disease control Sponsor: Jacobio Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new oral medication called JAB-2485 in adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will first determine the safest dose and then look for early signs that the drug can shrink tumors in specific cancers, including certain breast and lung cancers. The main goals are to understand the drug's safety profile and see if it shows any promise against these difficult-to-treat cancers.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100101, China
Henry Ford Health System
RECRUITING

Detroit, Michigan, 48202, United States
Jilin Cancer Hospital
RECRUITING

Changchun, Jilin, 130000, China
Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75230, United States
Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, 100101, China
Shandong Cancer Hospital
RECRUITING

Jinan, Shandong, 250117, China
University of Utah Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

ARID1A GENE MUTATION ER+ BREAST CANCER SMALL CELL LUNG CANCER (SCLC) SOLID TUMORS TRIPLE NEGATIVE BREAST CANCER (TNBC)